Repository logo
  • English
  • Srpski (lat)
  • Српски
Log In
Have you forgotten your password?
  1. Home
  2. Browse by Author

Browsing by Author "Stojiljkovic-Tamas, Olivera (57202112475)"

Filter results by typing the first few letters
Now showing 1 - 5 of 5
  • Results Per Page
  • Sort Options
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Incidence and mortality rates of Guillain-Barré syndrome in Serbia
    (2020)
    Stojanov, Aleksandar (57194143903)
    ;
    Berisavac, Ivana (6507392420)
    ;
    Bozovic, Ivo (57194468421)
    ;
    Arsenijevic, Mirjana (57357620400)
    ;
    Lukic-Rajic, Sonja (56516616500)
    ;
    Petrovic, Milutin (36969833200)
    ;
    Stojiljkovic-Tamas, Olivera (57202112475)
    ;
    Jovin, Zita (8208650200)
    ;
    Djordjevic, Gordana (35763715800)
    ;
    Jovanovic, Dejana (55419203900)
    ;
    Stojanovic, Miroslav (55442973200)
    ;
    Martic, Vesna (6602650915)
    ;
    Basta, Ivana (8274374200)
    ;
    Peric, Stojan (35750481700)
    Guillain-Barré syndrome (GBS) is an acute auto-immune polyradiculoneuropathy. A huge variety of GBS incidence and mortality rates has been noted across the world. The objective of the present multi-centric study was to assess the incidence and mortality rates of GBS during a 10-year period in Serbia. We collected data of adult GBS patients who were hospitalized from 2009 to 2018 in all five tertiary healthcare centers in Serbia. The incidence rates per 100 000 inhabitants with 95% confidence intervals (CI) were calculated and further corrected for the estimated number of patients hospitalized in secondary centers. Mortality rates were also assessed. GBS was considered severe if patients were not able to walk at least 10 m without assistance. Six hundred and forty GBS patients were registered in tertiary centers in a 10-year period. The proportion of severe cases was 75% at nadir, and 52% on discharge. GBS incidence rate in Serbia was 1.1 per 100 000 inhabitants, and estimated incidence if patients from secondary centers included 1.2 per 100 000. Peak incidence was observed during the sixth decade of life. During the acute phase, 5.6% of GBS patients died, while overall 9.7% of them died during 6-month period from disease onset. This study contributes to our knowledge about GBS epidemiology. Results will allow us to improve the diagnosis and treatment of GBS patients in Serbia. © 2020 Peripheral Nerve Society.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Incidence and mortality rates of Guillain-Barré syndrome in Serbia
    (2020)
    Stojanov, Aleksandar (57194143903)
    ;
    Berisavac, Ivana (6507392420)
    ;
    Bozovic, Ivo (57194468421)
    ;
    Arsenijevic, Mirjana (57357620400)
    ;
    Lukic-Rajic, Sonja (56516616500)
    ;
    Petrovic, Milutin (36969833200)
    ;
    Stojiljkovic-Tamas, Olivera (57202112475)
    ;
    Jovin, Zita (8208650200)
    ;
    Djordjevic, Gordana (35763715800)
    ;
    Jovanovic, Dejana (55419203900)
    ;
    Stojanovic, Miroslav (55442973200)
    ;
    Martic, Vesna (6602650915)
    ;
    Basta, Ivana (8274374200)
    ;
    Peric, Stojan (35750481700)
    Guillain-Barré syndrome (GBS) is an acute auto-immune polyradiculoneuropathy. A huge variety of GBS incidence and mortality rates has been noted across the world. The objective of the present multi-centric study was to assess the incidence and mortality rates of GBS during a 10-year period in Serbia. We collected data of adult GBS patients who were hospitalized from 2009 to 2018 in all five tertiary healthcare centers in Serbia. The incidence rates per 100 000 inhabitants with 95% confidence intervals (CI) were calculated and further corrected for the estimated number of patients hospitalized in secondary centers. Mortality rates were also assessed. GBS was considered severe if patients were not able to walk at least 10 m without assistance. Six hundred and forty GBS patients were registered in tertiary centers in a 10-year period. The proportion of severe cases was 75% at nadir, and 52% on discharge. GBS incidence rate in Serbia was 1.1 per 100 000 inhabitants, and estimated incidence if patients from secondary centers included 1.2 per 100 000. Peak incidence was observed during the sixth decade of life. During the acute phase, 5.6% of GBS patients died, while overall 9.7% of them died during 6-month period from disease onset. This study contributes to our knowledge about GBS epidemiology. Results will allow us to improve the diagnosis and treatment of GBS patients in Serbia. © 2020 Peripheral Nerve Society.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Recurrent Guillain-Barré Syndrome - Case Series
    (2019)
    Basta, Ivana (8274374200)
    ;
    Bozovic, Ivo (57194468421)
    ;
    Berisavac, Ivana (6507392420)
    ;
    Stojiljkovic-Tamas, Olivera (57202112475)
    ;
    Rajic, Sonja (56516616500)
    ;
    Dominovic-Kovacevic, Aleksandra (37028225600)
    ;
    Stojanov, Aleksandar (57194143903)
    ;
    Djordjevic, Gordana (35763715800)
    ;
    Jovanovic, Dejana (55419203900)
    ;
    Peric, Stojan (35750481700)
    Recurrent Guillain-Barré syndrome (RGBS) episodes appear in up to 6% of Guillain-Barré syndrome (GBS) patients. The purpose of this study was to identify patients with previous episodes of GBS and to assess their clinical features in a large cohort of adult GBS patients. GBS patients hospitalized at tertiary centers in three Balkan countries were included in the study (n = 404). We identified 13 (3.2%) patients with recurrent GBS (RGBS). The male to female ratio was 3: 1. All RGBS patients had two episodes of the disease. The most common GBS subtype in both episodes of the disease was acute inflammatory demyelinating polyradiculoneuropathy (AIDP) (77%, first episode; 85%, second episode). Around 23% of patients presented with a different variant during the second GBS attack. Disability seems to be equally severe at both episodes (P > 0.05). Recurrent GBS was registered in 3% of our GBS patients. The majority of them were younger males. Different GBS subtypes were found to recur. © 2019 Neurology India, Neurological Society of India.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Recurrent Guillain-Barré Syndrome - Case Series
    (2019)
    Basta, Ivana (8274374200)
    ;
    Bozovic, Ivo (57194468421)
    ;
    Berisavac, Ivana (6507392420)
    ;
    Stojiljkovic-Tamas, Olivera (57202112475)
    ;
    Rajic, Sonja (56516616500)
    ;
    Dominovic-Kovacevic, Aleksandra (37028225600)
    ;
    Stojanov, Aleksandar (57194143903)
    ;
    Djordjevic, Gordana (35763715800)
    ;
    Jovanovic, Dejana (55419203900)
    ;
    Peric, Stojan (35750481700)
    Recurrent Guillain-Barré syndrome (RGBS) episodes appear in up to 6% of Guillain-Barré syndrome (GBS) patients. The purpose of this study was to identify patients with previous episodes of GBS and to assess their clinical features in a large cohort of adult GBS patients. GBS patients hospitalized at tertiary centers in three Balkan countries were included in the study (n = 404). We identified 13 (3.2%) patients with recurrent GBS (RGBS). The male to female ratio was 3: 1. All RGBS patients had two episodes of the disease. The most common GBS subtype in both episodes of the disease was acute inflammatory demyelinating polyradiculoneuropathy (AIDP) (77%, first episode; 85%, second episode). Around 23% of patients presented with a different variant during the second GBS attack. Disability seems to be equally severe at both episodes (P > 0.05). Recurrent GBS was registered in 3% of our GBS patients. The majority of them were younger males. Different GBS subtypes were found to recur. © 2019 Neurology India, Neurological Society of India.
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Publication
    Self-reported autonomic dysfunction in a recovery phase of Guillain-Barré syndrome
    (2021)
    Arsenijevic, Mirjana (57357620400)
    ;
    Berisavac, Ivana (6507392420)
    ;
    Bozovic, Ivo (57194468421)
    ;
    Stojiljkovic-Tamas, Olivera (57202112475)
    ;
    Palibrk, Aleksa (57209500486)
    ;
    Lukic-Rajic, Sonja (56516616500)
    ;
    Vujovic, Balsa (57021631300)
    ;
    Peric, Stojan (35750481700)
    Objective: Autonomic dysfunction occurs in approximately two-thirds of Guillain-Barré syndrome (GBS) patients in the acute phase of the disease. Although improving over time, subclinical autonomic involvement may be present for 3–8 years after the GBS episode. The aim of this study was to determine the frequency of self-reported autonomic disorders in GBS patients three and six months after disease onset compared to healthy controls (HCs). Methods: Our study included adult patients diagnosed with GBS from May 2017 until May 2018 in seven healthcare centers (67.6 % with demyelinating and 13.6 % with axonal syubtype). Functional disability was assessed by the Guillain-Barré syndrome disability scale (GDS). Each subject filled in the Serbian version of the SCOPA-Aut questionnaire. Using GDS and SCOPA-Aut, patients were tested at month 3 (M3) (n = 71) and month 6 (M6) (n = 70) from symptom onset. Results: Dysautonomia was more common in patients with GBS compared to HCs at M3 (p < 0.01), while there was no difference at M6 (p > 0.05). Among autonomic disorders, constipation, complications to pass stool, and orthostatic hypotension were the most frequently reported. Patients with axonal variants had worse total SCOPA-Aut scores at M3 in comparison to AIDP patients (11.7 ± 10.1 vs. 6.1 ± 5.1, p < 0.05). GDS score correlated with the total SCOPA-Aut score. Conclusion: Autonomic symptoms are common in GBS patients during the recovery phase. They are more pronounced in patients with axonal forms of GBS and those with a higher degree of functional disability. © 2020 Elsevier B.V.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Privacy policy
  • End User Agreement
  • Send Feedback